/SMMT
SMMT Stock - Summit Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$16.81-1.35%
$0.23 (-1.35%) • Jan 13
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.11
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+46.8%upside
Target: $24.68
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SMMT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.64 – $16.98
TARGET (TP)$24.67
STOP LOSS$15.47
RISK/REWARD1:5.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.51
52W High$36.91
52W Low$15.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $704,295 | $1.81M | $860,000 |
| Gross Profit | $-15,007,000 | $-2,050,000 | $-1,810,000 | $1.81M | $860,000 |
| Gross Margin | N/A | N/A | -257.0% | 100.0% | 100.0% |
| Operating Income | $313,000 | $-89,736,000 | $-59,633,000 | $-86,186,000 | $-53,193,000 |
| Net Income | $-221,315,000 | $-614,928,000 | $-78,782,000 | $-88,602,000 | $-52,697,000 |
| Net Margin | N/A | N/A | -11185.9% | -4897.8% | -6127.6% |
| EPS | $-0.31 | $-0.99 | $-0.41 | $-0.96 | $-0.76 |
Company Overview
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SMMTBeat Rate
62%
Last 13 quarters
Avg Surprise
-44.2%
EPS vs Estimate
Beats / Misses
8/4
1 met exactly
Latest EPS
$-1.04
Q3 2025
EPS Surprise History
Q4 23
No data
Q2 24
0.0%
$-0.06vs$-0.06
Q3 24
+16.7%
$-0.05vs$-0.06
Q4 24
-14.3%
$-0.08vs$-0.07
Q1 25
+2.2%
$-0.08vs$-0.08
Q2 25
+3.2%
$-0.09vs$-0.09
Q3 25
-736.9%
$-0.76vs$-0.09
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $-0.27 | — | — | — |
Q3 2025 | Aug 11, 2025 | — | $-1.04 | — | — |
Q3 2025 | Aug 11, 2025 | $-0.09 | $-0.76 | -736.9% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-0.09 | $-0.09 | +3.2% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $-0.08 | $-0.08 | +2.2% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $-0.06 | $-0.06 | 0.0% | = MET |
Q4 2023 | Nov 7, 2023 | — | $-0.03 | — | — |
Q3 2023 | Aug 9, 2023 | — | $-0.02 | — | — |
Q2 2023 | May 11, 2023 | — | $-0.06 | — | — |
Q1 2023 | Mar 9, 2023 | $-0.26 | $-0.07 | +73.1% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.26 | $-0.14 | +46.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.27 | $-0.17 | +37.0% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.28 | $-0.22 | +21.4% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.27 | $-0.28 | -3.7% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.29 | $-0.20 | +31.0% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.18 | $-0.27 | -50.0% | ✗ MISS |
Q2 2021 | May 17, 2021 | — | $-1.05 | — | — |
Latest News
Loading news...
Frequently Asked Questions about SMMT
What is SMMT's current stock price?
Summit Therapeutics Inc. (SMMT) is currently trading at $16.81 per share. The stock has moved -1.35% today.
What is the analyst price target for SMMT?
The average analyst price target for SMMT is $24.67, based on 1 analyst.
What sector is Summit Therapeutics Inc. in?
Summit Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SMMT's market cap?
Summit Therapeutics Inc. has a market capitalization of $12.51 billion, making it a large-cap company.
Does SMMT pay dividends?
No, Summit Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASND
Ascendis Pharma A/S
$215.05
Mkt Cap: $13.0B
BBIO
BridgeBio Pharma, Inc.
$79.11
Mkt Cap: $15.1B
EXAS
Exact Sciences Corporation
$102.25
Mkt Cap: $19.4B
IONS
Ionis Pharmaceuticals, Inc.
$79.48
Mkt Cap: $12.6B
MRNA
Moderna, Inc.
$39.60
Mkt Cap: $15.5B
RNA
Avidity Biosciences, Inc.
$72.43
Mkt Cap: $9.5B
ROIV
Roivant Sciences Ltd.
$23.44
Mkt Cap: $16.3B
RPRX
Royalty Pharma plc
$40.36
Mkt Cap: $17.5B
RVMD
Revolution Medicines, Inc.
$119.95
Mkt Cap: $23.2B
UHS
Universal Health Services, Inc.
$201.81
Mkt Cap: $13.0B
Explore stocks similar to SMMT for comparison